Free Trial

Masimo (NASDAQ:MASI) Rating Lowered to Market Perform at Raymond James Financial

Masimo logo with Medical background
Image from MarketBeat Media, LLC.

Key Points

  • Raymond James downgraded Masimo from "outperform" to "market perform," joining several other firms that have trimmed ratings; the Street consensus is a "Reduce" rating with a $181.17 average price target.
  • Shares opened at $176.89 (1-year range $125.94–$179.00) with a market cap of $9.5 billion, a negative P/E (-16.78), and 50-/200-day SMAs at $159.23 and $148.12 respectively, showing the stock remains above key moving averages despite analyst downgrades.
  • Institutional investors own roughly 86% of the company, and large managers like T. Rowe Price have recently increased holdings, signaling significant institutional involvement despite mixed analyst sentiment.
  • Five stocks to consider instead of Masimo.

Masimo (NASDAQ:MASI - Get Free Report) was downgraded by equities researchers at Raymond James Financial from an "outperform" rating to a "market perform" rating in a research report issued to clients and investors on Friday.

Several other research firms have also issued reports on MASI. Weiss Ratings reissued a "sell (d)" rating on shares of Masimo in a research report on Thursday, January 22nd. Wolfe Research lowered shares of Masimo from a "strong-buy" rating to a "hold" rating in a research note on Thursday, February 19th. Stifel Nicolaus set a $180.00 target price on shares of Masimo in a report on Tuesday, February 17th. Wells Fargo & Company upgraded Masimo to a "hold" rating in a research report on Wednesday, March 18th. Finally, BTIG Research cut Masimo from a "buy" rating to a "neutral" rating in a research report on Wednesday, February 18th. Eight equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Reduce" and a consensus price target of $181.17.

Check Out Our Latest Analysis on MASI

Masimo Price Performance

Shares of NASDAQ MASI opened at $176.89 on Friday. The company has a current ratio of 2.49, a quick ratio of 1.47 and a debt-to-equity ratio of 0.72. The stock has a fifty day simple moving average of $159.23 and a two-hundred day simple moving average of $148.12. Masimo has a 1-year low of $125.94 and a 1-year high of $179.00. The firm has a market cap of $9.50 billion, a price-to-earnings ratio of -16.78, a price-to-earnings-growth ratio of 1.80 and a beta of 1.21.

Institutional Trading of Masimo

Hedge funds and other institutional investors have recently bought and sold shares of the company. Corient Private Wealth LLC boosted its holdings in Masimo by 1.2% in the 4th quarter. Corient Private Wealth LLC now owns 340,230 shares of the medical equipment provider's stock valued at $44,250,000 after purchasing an additional 4,015 shares during the period. Caitong International Asset Management Co. Ltd bought a new position in shares of Masimo in the fourth quarter worth $116,000. Pacer Advisors Inc. increased its holdings in shares of Masimo by 21.1% in the fourth quarter. Pacer Advisors Inc. now owns 7,360 shares of the medical equipment provider's stock worth $957,000 after purchasing an additional 1,280 shares during the period. Virtu Financial LLC purchased a new stake in shares of Masimo in the fourth quarter worth $258,000. Finally, T. Rowe Price Investment Management Inc. raised its position in shares of Masimo by 9.6% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,330,158 shares of the medical equipment provider's stock worth $303,061,000 after buying an additional 203,395 shares in the last quarter. Institutional investors own 85.96% of the company's stock.

Masimo Company Profile

(Get Free Report)

Masimo NASDAQ: MASI is a global medical technology company specializing in noninvasive monitoring solutions. The company's flagship technology, Masimo SET® (Signal Extraction Technology), enhances the accuracy of pulse oximetry in challenging clinical conditions. Beyond pulse oximetry, Masimo's portfolio extends to brain function monitoring, regional oximetry, and acoustic respiration rate monitoring, serving critical, acute, and ambulatory care settings.

In addition to its core monitoring technologies, Masimo offers a range of patient cables, sensors, and connectivity platforms designed to integrate with hospital information systems and remote monitoring applications.

See Also

Analyst Recommendations for Masimo (NASDAQ:MASI)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Masimo Right Now?

Before you consider Masimo, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Masimo wasn't on the list.

While Masimo currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Stocks That Will Be Magnificent in 2026 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines